Prospects of engineered bacteria-assisted CAR T Cell therapy in gastrointestinal cancers

The high incidence and mortality rates associated with gastrointestinal cancers represent a significant global health challenge. In recent years, CAR T cell therapy has emerged as a promising immunotherapeutic approach, demonstrating favorable clinical outcomes. However, the application of tradition...

Full description

Saved in:
Bibliographic Details
Published inOncology reviews Vol. 19; p. 1581856
Main Authors Zhang, Qingqing, Song, Xiao, Liu, Junhong, Zhou, Xuejiao
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 14.04.2025
Subjects
CAR T cell therapy
engineered bacteria
gastrointestinal cancers
immunotherapy
Oncology Reviews
tumor microenvironment
gastrointestinal cancers
CAR T cell therapy
tumor microenvironment
engineered bacteria
immunotherapy
Online AccessGet full text

Cover

More Information
Summary:The high incidence and mortality rates associated with gastrointestinal cancers represent a significant global health challenge. In recent years, CAR T cell therapy has emerged as a promising immunotherapeutic approach, demonstrating favorable clinical outcomes. However, the application of traditional CAR T cell therapy in gastrointestinal cancers faces numerous challenges, including the suppressive tumor microenvironment and limitations in anti-tumor efficacy. The application of engineered bacteria offers a novel strategy to enhance CAR T cell therapy by modulating the tumor microenvironment and boosting immune responses, potentially leading to improved therapeutic outcomes. This review synthesizes the current research advancements related to engineered bacteria-assisted CAR T cell therapy in gastrointestinal cancers, exploring its underlying mechanisms, clinical applications, and future developmental directions.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Mauro Cives, University of Bari Aldo Moro, Italy
Eleonora Pelle, Moffitt Cancer Center, United States
Reviewed by: Barbara Mandriani, G. Pascale National Cancer Institute Foundation (IRCCS), Italy
ISSN:1970-5557
1970-5565
1970-5557
DOI:10.3389/or.2025.1581856